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Abstract
Gamma-hydroxybutyrate (GHB or XyremR) is frequently used in humans for several clinical indications, including
anesthesia, narcolepsy/cataplexy, and alcohol-withdrawal symptoms. Pharmacological effects induced in the brain
by therapeutic doses of XyremR are generally GABAergic-dependent. These effects allow sedation, stress/anxiety
reduction, deep sleep induction, decrease of neuroinflammation, and neuroprotection. Furthermore, XyremR promotes
the expression of pivotal genes reducing toxic proteinopathies, as demonstrated in laboratory animal models. Altogether,
these data represent additional evidence to suggest that XyremR may be tested during repeated short periods in
populations at risk for Alzheimer’s disease.
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Background
Gamma-hydroxybutyrate (GHB, sodium oxybate, or
XyremR), which has long been approved by the U.S.
Food and Drug Administration for the treatment of
narcolepsy, cataplexy, or sleep disorders, is also com-
monly used in humans for anesthesia and the manage-
ment of alcohol-withdrawal symptoms. Because GHB
treatment efficiently improves neuropathological and
cognitive symptoms in experimental or animal models
of Alzheimer’s disease (AD), we review herein the es-
sential positive effects of GHB supporting the possibil-
ity to use this drug in humans to prevent or delay the
development of AD. Assessment of AD occurrence in
aged narcoleptic patients treated with GHB compared
to controls receiving another drug may also be an inter-
esting strategy to check the therapeutic potential of
GHB against AD. Thus, the present paper does not
pretend to have the solution for the very complex AD
issue. It must only be considered as a simple view
suggesting a new option that will need a careful evalu-
ation in selected groups of patients under strict medical
supervision before any confirmation. Because AD re-
mains a major health concern with no effective therapy
available, every suggestion to prevent irreversible brain
lesions or to improve patients’ lives needs to be consid-
ered with specific attention.
Main text
Pre-clinical AD lasts several years or decades until the dis-
rupted turnover and accumulation of Aβ in the brain
reaches a critical level inducing the amyloid cascade. Dur-
ing this period, the activity of several critical proteins,
regulated by multiple inherited or environmental factors,
participates in the homeostasis of Aβ. It has recently been
shown that GHB, administered at pharmacological dos-
ages to rats or mice, modifies the brain transcriptome and
induces several proteins exerting a beneficial role against
proteinopathies, including AD [1, 2]. Among the genes
upregulated by GHB, Neprilysin (NEP), Heat shock
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protein 70 (HSP70), and choline acetyltransferase
(ChAT) are of deep interest for the management of the
disease. Chronic administration of GHB to tg 2576 or
phosphoramidon-treated mice reduced Aβ oligomers in
the brain and normalized mnesic deficits compared to
non-treated mice [3]. These beneficial effects were due
to the ability of GHB to induce the expression of the
endopeptidase NEP that potentiates the degradative clear-
ance of Aβ oligomers. Therapeutic doses of GHB also
promote HSP70, the ubiquitous class of ATP-dependent
chaperone protein, which plays an important role in pre-
venting protein misfolding and aggregation involved in
AD pathogenesis [4]. Moreover, via the induction of
ChAT, GHB could also improve the deficient cholinergic
transmission [2].
Chronic GHB treatment may also have other targets of
interest to delay or reduce AD, which is thought to be
multi-factorial in about 95 % of patients. Interestingly,
several pharmacological investigations revealed that the
therapeutic doses of GHB evoke a large brain GABAer-
gic potentiation which may subsequently generate the
modulation of several other cellular components or fac-
tors [5]. Since GABA-A receptor agonists have shown
neuroprotective effects against Aβ-induced neurotoxicity
in animal and in vitro models, GHB-evoked GABAergic
activation may be used at early stages to prevent the de-
velopment of cognitive deficits [6]. At a metabolic point
of view, the GABA shunt pathway has been proposed as
an important source of energy in the situation of homeo-
stasis failure, stress, hypoxia, and alteration of protein
degradation. A part of exogenous GHB degradation is dir-
ectly linked to the production of intermediates of this
GABA shunt, which could be potentiated by the drug. In
addition, it is generally thought that GHB reduces glucose
oxidation and shifts the general energy metabolism in the
direction of the phosphate shunt pathway [7]. This effect,
added to the hyperactivity of NADP-dependent GHB de-
hydrogenase, contributes to the synthesis of NADPH and
to the trapping of reactive oxidative agents, leading to the
reduction of Aβ-induced vascular and neuronal stress.
The possibility of GHB-induced oxidative stress was
mentioned by an isolated in vitro study using rat tissue
[8], but this question has never been documented in nar-
coleptic patients treated for many years with sodium oxy-
bate (GHB) and the majority of these patients exhibited a
good tolerability and efficacy for GHB [9]. The specific
GABAergic profile of GHB at therapeutic doses could also
possess beneficial properties on neuroinflammatory pro-
cesses, which are key components of many neurodeg-
enerative diseases, including AD. The brain level of GABA
has been correlated to the progression of neuroinflamma-
tory disorders [10]. In line with these data, the activation
of GABA-A and GABA-B receptors decreased pro-
inflammatory cytokines [10]. As GHB-related mechanism
of action involves GABA-A and GABA-B receptors, GHB
may exert anti-neuroinflammatory effects via the reduc-
tion of pro-inflammatory cytokines. However, appropriate
experiments are required to check this hypothesis since
the specific role of GHB on neuroinflammation has never
been investigated.
Another property of GHB which may be interesting for
AD prevention is its ability to induce sleep and to improve
sleep architecture, particularly in promoting slow-wave
sleep and delta power with a reduction of nocturnal awak-
ening periods [11, 12]. There is growing evidence that
sleep disturbances might be an early manifestation of AD
and that the circadian rhythms are affected [13–15].
Whether sleep and/or biological rhythm-related problems
may be causal factors or outcomes of neurodegenerative
diseases remains a matter of speculation. However, note-
worthy is the fact that the induction of sleep in a drosoph-
ila model of AD has successfully reversed memory defects
[16]. In addition, it has been shown that the enhancement
of GABAergic inhibition significantly rescued the slow-
wave activity severely altered in a mouse model of AD
[17]. Chronic sleep deprivation in this AD mouse model
increased mitochondrial damages, caspase activation, and
neuronal apoptosis in the hippocampus. These alterations
were also observed in the wild-type littermates [18]. Mice
that experienced sleep deprivation or an abnormal sleep-
wake cycle had a significant increase in Aβ plaque path-
ology [15]. In humans, the non-REM sleep induced by a
short period of sodium oxybate (GHB) treatment seems to
be beneficial for the consolidation of declarative memory
[19]. However, to get more valuable insights into the role
of GHB against AD, it will be fundamental to compare, in
narcoleptic populations, AD symptom occurrence in aged
patients treated with GHB for several months/years versus
control subjects treated with another drug. In case this
comparative analysis confirms a beneficial action of GHB,
people at risk (familial or environmental factors) for AD
may be treated preventively with repeated periods of noc-
turnal GHB under medical supervision, at the onset of
aging. Indeed, the appropriate protocols and dose regimens
for this preventive GHB neuroprotective treatment will re-
quire a strict medical control taking into account the
specific profile of each patient [20]. Hopefully, this strategy
may help to prevent, reduce, or delay for several years the
occurrence of irreversible brain lesions and AD symptoms.
It has been shown that GABAergic system dysfunction
may contribute to cognitive impairment in humans and
significant reductions in GABA levels have been described
in severe cases of AD [21]. These decreases, beginning in
middle age and impacting working memory, have been
confirmed by magnetic resonance spectroscopy of the
brain [22]. Additionally, a recent review quoted the exist-
ence of multiple alterations of the GABAergic neurotrans-
mission in AD patients [23].
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Conclusions
GHB or XyremR is generally a safe drug when given under
medical supervision. Its genomic and pharmacological
effects strongly support a preventive action of this drug to
reduce the occurrence of cognitive deficits in selected pa-
tients at risk for AD (aging, familial, or genetic heritage).
The drug is proposed to be given for a repeated period at
night, in a similar manner to the strategy used for the
treatment of narcolepsy. However, we do not suggest a
chronic routine administration of GHB, but only short
sequences of treatment (eight consecutive days every two
months, for example, to be adapted following biological
markers). These series of short periods of administration
seem to be sufficient to reduce amyloid peptide accumula-
tion, as demonstrated after NEP inhibition by phosphora-
midon in mice [3]. In addition, we think that the proposed
treatment should be delivered from the very early phase of
the disease in order to increase the chance of effectiveness
in preventing neurodegenerative processes. Again, and
more importantly, we would like to recall that the present
paper cannot warrant the success of the proposed treat-
ment as it constitutes only an opinion or viewpoint, which
lacks for the moment experimental data in humans. It
should be mentioned that acute or sub-chronic use of
the drug induces sometimes modest transient amnestic
effects. Marked amnesia was reported following inges-
tion of illicit GHB, co-administered with antidepres-
sants or ethanol, in recreative or criminal situations
involving use/misuse of the drug. Moreover, as with
many other drugs which are used daily in the human
clinic (benzodiazepines, opiates, antidepressants, etc.),
abuse uses of high concentrations of GHB may be addict-
ive and/or may induce severe side effects (respiratory de-
pression, coma, death). Therefore, the therapeutic use of
GHB suggested herein may only be envisioned under
strict medical supervision. In the authors’ opinion, the
synthesis of more efficient compounds to replace GHB,
especially in the domain of neuroprotection, has to focus
on substances with long-lasting effects and strong agonis-
tic activities for both GHB and GABA-B receptors [5].
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